Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: Implications for their effects on innate immune function and osteoclastogenesis

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 111, Issue 2, 2011, Pages 196-204

  Reuben, Jayne S ^a   Dinh, Laura ^a   Lee, Jane ^a   Stateson, Jonathan ^a   Kamara, Harold ^a   Xiang, Lilin ^a   Opperman, Lynne A ^a  

^a BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; IBANDRONIC ACID; SOCS3 PROTEIN, MOUSE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MOUSE; OSTEOCLAST;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; CLODRONIC ACID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNITY, INNATE; MACROPHAGES; MICE; OSTEOCLASTS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 78651423593     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2010.09.068     Document Type: Article

References (79)

1. P. Rotjanapan Effect of zoledronic acid on bone pain secondary to metastatic bone disease Med Health R I 92 2009 27 29
2. T. Osanai, T. Tsuchiya, and M. Sugawara Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy J Orthop Sci 14 2009 224 227 [PubMed]
3. T. Mert, I. Gunay, I. Ocal, A.I. Guzel, T.C. Inal, and L. Sencar Macrophage depletion delays progression of neuropathic pain in diabetic animals Naunyn Schmiedebergs Arch Pharmacol 379 2009 445 452 [PubMed]
4. L. Costa, and P.P. Major Effect of bisphosphonates on pain and quality of life in patients with bone metastases Nat Clin Pract Oncol 6 2009 163 174 [PubMed]
5. A. Cheng, A. Mavrokokki, G. Carter, B. Stein, N.L. Fazzalari, and D.F. Wilson The dental implications of bisphosphonates and bone disease Aust Dent J 50 Suppl 2 2005 S4 S13 [PubMed]
6. A. Bamias, E. Kastritis, C. Bamia, L.A. Moulopoulos, I. Melakopoulos, and G. Bozas Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 2005 8580 8587 [PubMed]
7. N. Price, A. Lipton, V.K. Jain, and S. Ruggiero Prevention and management of osteonecrosis of the jaw associated with bisphosphonate therapy Support Cancer Ther 2 2004 14 17 [PubMed]
8. M.S. Greenberg Intravenous bisphosphonates and osteonecrosis Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98 2004 259 260 [PubMed]
9. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 2003 1115 1117 [PubMed]
10. G.D. Carter, and A.N. Goss Bisphosphonates and avascular necrosis of the jaws Aust Dent J 48 2003 268 [PubMed]
11. R.G. Russell, M.J. Rogers, J.C. Frith, S.P. Luckman, F.P. Coxon, and H.L. Benford The pharmacology of bisphosphonates and new insights into their mechanisms of action J Bone Miner Res 14 Suppl 2 1999 53 65 [PubMed]
12. M.J. Rogers, S. Gordon, H.L. Benford, F.P. Coxon, S.P. Luckman, and J. Monkkonen Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 12 Suppl 2000 2961 2978 [PubMed]
13. R. Derijk, N. van Rooijen, F.J. Tilders, H.O. Besedovsky, R.A. Del, and F. Berkenbosch Selective depletion of macrophages prevents pituitary-adrenal activation in response to subpyrogenic, but not to pyrogenic, doses of bacterial endotoxin in rats Endocrinology 129 1991 330 338
14. A. Bergh, J.E. Damber, and N. van Rooijen Liposome-mediated macrophage depletion: an experimental approach to study the role of testicular macrophages in the rat J Endocrinol 136 1993 407 413 [PubMed]
15. J.P. Camilleri, A.S. Williams, N. Amos, A.G. Douglas-Jones, W.G. Love, and B.D. Williams Methods for assessing splenic macrophage depletion by liposome encapsulated clodronate Inflamm Res 44 1995 152 157 [PubMed]
16. J.E. Dunford, M.J. Rogers, F.H. Ebetino, R.J. Phipps, and F.P. Coxon Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases J Bone Miner Res 21 2006 684 694 [PubMed]
17. G.A. Rodan, and A.A. Reszka Bisphosphonate mechanism of action Curr Mol Med 2 2002 571 577 [PubMed]
18. F. Bauss, and R.C. Schimmer Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis Ther Clin Risk Manag 2 2006 3 18
19. D. Vomvas, V. Vassiliou, D. Papavasileiou, C. Kalogeropoulou, O. Nicolatou-Galitis, and D. Kardamakis Osteonecrosis of the jaw in a patient treated with ibandronate J BUON 13 2008 441 442 [PubMed]
20. N.J. Malden, and A.Y. Pai Oral bisphosphonate associated osteonecrosis of the jaws: three case reports Br Dent J 203 2007 93 97 [PubMed]
21. C.A. Migliorati, B.N. Armonis, and O. Nicolatou-Galitis Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106 2008 e18 e21 [PubMed]
22. R.E. Marx, Y. Sawatari, M. Fortin, and V. Broumand Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 63 2005 1567 1575 [PubMed]
23. K. Barker, and S. Rogers Bisphosphonate-associated osteonecrosis of the jaws: a guide for the general dental practitioner Dent Update 33 2006 270 272 5 [PubMed]
24. J.G. Bode, A. Nimmesgern, J. Schmitz, F. Schaper, M. Schmitt, and W. Frisch LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages FEBS Lett 463 1999 365 370 [PubMed]
25. M.A. Cassatella, S. Gasperini, C. Bovolenta, F. Calzetti, M. Vollebregt, and P. Scapini Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation Blood 94 1999 2880 2889 [PubMed]
26. J. Schmitz, M. Weissenbach, S. Haan, P.C. Heinrich, and F. Schaper SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130 J Biol Chem 275 2000 12848 12856 [PubMed]
27. B.A. Croker, D.L. Krebs, J.G. Zhang, S. Wormald, T.A. Willson, and E.G. Stanley SOCS3 negatively regulates IL-6 signaling in vivo Nat Immunol 4 2003 540 545 [PubMed]
28. R. Lang, A.L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, and J.N. Ihle SOCS3 regulates the plasticity of gp130 signaling Nat Immunol 4 2003 546 550 [PubMed]
29. U. Lehmann, J. Schmitz, M. Weissenbach, R.M. Sobota, M. Hortner, and K. Friederichs SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130 J Biol Chem 278 2003 661 671 [PubMed]
30. P.K. Wong, P.J. Egan, B.A. Croker, K. O'Donnell, N.A. Sims, and S. Drake SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis J Clin Invest 116 2006 1571 1581 [PubMed]
31. S.W. Fox, S.J. Haque, A.C. Lovibond, and T.J. Chambers The possible role of TGF-betainduced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro J Immunol 170 2003 3679 3687 [PubMed]
32. + dendritic cellderived osteoclastogenesis and severe alveolar bone loss Infect Immun 77 2009 2000 2009 [PubMed]
33. M. Ohishi, Y. Matsumura, D. Aki, R. Mashima, K. Taniguchi, and T. Kobayashi Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines J Immunol 174 2005 3024 3031 [PubMed]
34. C. Vincent, M. Kogawa, D.M. Findlay, and G.J. Atkins The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions J Bone Miner Metab 27 2009 114 119
35. X. Deng, R. Tamai, Y. Endo, and Y. Kiyoura Alendronate augments interleukin-1beta release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1 Toxicol Appl Pharmacol 235 2009 97 104 [PubMed]
36. J.F. Van Offel, E.J. Dombrecht, and C.H. Bridts Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes Cytokines 31 2005 298 304
37. K. Takagi, M. Takagi, S. Kanangat, K.J. Warrington, H. Shigemitsu, and A.E. Postlethwaite Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways J Immunol 174 2005 1801 1810 [PubMed]
38. R.E. Hewitt, A. Lissina, A.E. Green, E.S. Slay, D.A. Price, and A.K. Sewell The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins Clin Exp Immunol 139 2005 101 111 [PubMed]
39. D. Santini, M.E. Fratto, B. Vincenzi, A. La Cesa, C. Dianzani, and G. Tonini Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities Biodrugs 18 2004 269 278 [PubMed]
40. P. Pietschmann, P. Stohlawetz, S. Brosch, G. Steiner, J.S. Smolen, and M. Peterlik The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells Calcif Tissue Int 63 1998 325 330 [PubMed]
41. J. Monkkonen, J. Simila, and M.J. Rogers Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro Life Sci 62 1998 PL95 PL102 [PubMed]:PL95-102
42. F. Bauss, and R.G. Russell Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing Osteoporos Int 15 2004 423 433 [PubMed]
43. F. Bauss, M. Wagner, and L.H. Hothorn Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats J Rheumatol 29 2002 990 998 [PubMed]
44. J. Barrett, E. Worth, F. Bauss, and S. Epstein Ibandronate: a clinical pharmacological and pharmacokinetic update J Clin Pharmacol 44 2004 951 965 [PubMed]
45. K. Vahtsevanos, A. Kyrgidis, E. Verrou, E. Katodritou, S. Triaridis, and C.G. Andreadis Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356 5362 [PubMed]
46. S. Suri, J. Monkkonen, M. Taskinen, J. Pesonen, M.A. Blank, and R.J. Phipps Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity Bone 29 2001 336 343 [PubMed]
47. A. Alakangas, K. Selander, M. Mulari, J. Halleen, P. Lehenkari, and J. Mnkknen Alendronate disturbs vesicular trafficking in osteoclasts Calcif Tissue Int 70 2002 40 47 [PubMed]
48. M. Debidda, L. Wang, H. Zang, V. Poli, and Y. Zheng A role of STAT3 in Rho GTPase-regulated cell migration and proliferation J Biol Chem 280 2005 17275 17285 [PubMed]
49. M.A. Scheper, A. Badros, R. Chaisuparat, K.J. Cullen, and T.F. Meiller Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis Br J Haematol 144 2009 667 676
50. A. Kyrgidis Novel hypotheses in the etiopathogenesis of bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 67 2009 2554 [PubMed]
51. A. Naidu, P.C. Dechow, R. Spears, J.M. Wright, H.P. Kessler, and L.A. Opperman The effects of bisphosphonates on osteoblasts in vitro Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106 2008 5 13 [PubMed]
52. J. Biewenga, M.B. van der Ende, L.F. Krist, A. Borst, M. Ghufron, and N. van Rooijen Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant Cell Tissue Res 280 1995 189 196 [PubMed]
53. R. Rezzani, L. Rodella, and R.G. Ventura Depletion of thymic macrophages in the rat by liposome-encapsulated dichloromethylene diphosphonate Arch Histol Cytol 58 1995 427 433 [PubMed]
54. J.T. Berg, S.T. Lee, T. Thepen, C.Y. Lee, and M.F. Tsan Depletion of alveolar macrophages by liposome-encapsulated dichloromethylene diphosphonate J Appl Physiol 74 1993 2812 2819 [PubMed]
55. A.J. Pinto, D. Stewart, N. van Rooijen, and P.S. Morahan Selective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene diphosphonate: effects on antimicrobial resistance J Leukoc Biol 49 1991 579 586 [PubMed]
56. N. Van Rooijen, N. Kors, M. van der Ende, and C.D. Dijkstra Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate Cell Tissue Res 260 1990 215 222
57. A.S. Banks, S.M. Davis, S.H. Bates, and M.G. Myers Jr Activation of downstream signals by the long form of the leptin receptor J Biol Chem 275 2000 14563 14572 [PubMed]
58. T. Kordula, M. Bugno, J. Goldstein, and J. Travis Activation of signal transducer and activator of transcription-3 (STAT3) expression by interferon-gamma and interleukin-6 in hepatoma cells Biochem Biophys Res Commun 216 1995 999 1005 [PubMed]
59. Z. Zhong, Z. Wen, and J.E. Darnell Jr STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science 264 1994 95 98
60. D.S. Finbloom, and K.D. Winestock IL-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes J Immunol 155 1995 1079 1090 [PubMed]
61. M. Nielsen, A. Svejgaard, S. Skov, and N. Odum Interleukin-2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes Eur J Immunol 24 1994 3082 3086 [PubMed]
62. S.S. Tian, P. Lamb, H.M. Seidel, R.B. Stein, and J. Rosen Rapid activation of the STAT3 transcription factor by granulocyte colonystimulating factor Blood 84 1994 1760 1764 [PubMed]
63. A. Sasaki, H. Yasukawa, A. Suzuki, S. Kamizono, T. Syoda, and I. Kinjyo Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain Genes Cells 4 1999 339 351 [PubMed]
64. L. Rui, M. Yuan, D. Frantz, S. Shoelson, and M.F. White SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 J Biol Chem 277 2002 42394 42398 [PubMed]
65. A.A. Reszka, J.M. Halasy-Nagy, P.J. Masarachia, and G.A. Rodan Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J Biol Chem 274 1999 34967 34973 [PubMed]
66. J.R. Green, and P. Clezardin Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis Am J Clin Oncol 25 Suppl 1 2002 S3 S9 [PubMed]
67. S. Aksoy, H. Abali, M. Dincer, S. Kilickap, I. Gullu, and G. Tekuzman Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties Med Hypotheses 62 2004 942 944 [PubMed]
68. 2+ signaling of human thyroid carcinoma cell lines Anticancer Res 24 2004 1617 1623 [PubMed]
69. L. Costantino, and D. Barlocco STAT 3 as a target for cancer drug discovery Curr Med Chem 15 2008 834 843 [PubMed]
70. M. Kortylewski, R. Jove, and H. Yu Targeting STAT3 affects melanoma on multiple fronts Cancer Metastasis Rev 24 2005 315 327 [PubMed]
71. M. Kortylewski, and H. Yu Role of STAT3 in suppressing anti-tumor immunity Curr Opin Immunol 20 2008 228 233 [PubMed]
72. E. Devarajan, and S. Huang STAT3 as a central regulator of tumor metastases Curr Mol Med 9 2009 626 633 [PubMed]
73. A. Krause, N. Scaletta, J.D. Ji, and L.B. Ivashkiv Rheumatoid arthritis synoviocyte survival is dependent on STAT3 J Immunol 169 2002 6610 6616 [PubMed]
74. H. Yasukawa, M. Ohishi, H. Mori, M. Murakami, T. Chinen, and D. Aki IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages Nat Immunol 4 2003 551 556 [PubMed]
75. C. Niemand, A. Nimmesgern, S. Haan, P. Fischer, F. Schaper, and R. Rossaint Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling. 3 J Immunol 170 2003 3263 3272 [PubMed]
76. X. Liu, Y. Zhang, Y. Yu, X. Yang, and X. Cao SOCS3 promotes TLR4 response in macrophages by feedback inhibiting TGF-beta1/SMAD3 signaling Mol Immunol 45 2008 1405 1413 [PubMed]
77. T. Kaneda, T. Nojima, M. Nakagawa, A. Ogasawara, H. Kaneko, and T. Sato Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappaB ligand and macrophage-colonystimulating factor J Immunol 165 2000 4254 4263 [PubMed]
78. M. Ruan, L. Pederson, E.W. Bradley, A.M. Bamberger, and M.J. Oursler Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis Endocrinology 151 2010 1713 1722 [PubMed]
79. K.A. Sutherland, H.L. Rogers, D. Tosh, and M.J. Rogers RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro Arthritis Res Ther 11 2009 R58 [PubMed]